Carbylan BioSurgery, Inc. Announces Appointment of President and CEO to Lead Company Through Next Phase of Development

  Carbylan BioSurgery, Inc. Announces Appointment of President and CEO to Lead
  Company Through Next Phase of Development

Business Wire

PALO ALTO, Calif. -- July 16, 2013

Carbylan BioSurgery, Inc., a biotechnology company focused on the development
and commercialization of advanced biomaterial-based joint therapies to treat
pain associated with osteoarthritis, announced that it has appointed David M.
Renzi as president, chief executive officer and member of the board of
directors. The appointment of Mr. Renzi, a proven operational executive,
signals a renewed focus on the Company’s long-term growth strategy and a
dedication to product development and commercialization. The Company also
announced that Samuel Lynch, D.M.D., D.M.Sc. has been appointed chairman of
Carbylan’s board of directors.

Commenting on Mr. Renzi’s appointment, Dr. Lynch stated, “Given David’s
extensive experience in both public and private medical device companies, the
board of directors is delighted that he has joined Carbylan as we continue the
development process of the Company’s next generation injectable technology for
the treatment of joint pain.” Mr. Renzi will lead Carbylan as it enters its
pivotal clinical trial utilizing the Company’s proprietary hyaluronan-based
hydrogel which is combined with a low dose corticosteroid. This unique
technology is designed to provide rapid and long-lasting relief of the pain
associated with osteoarthritis using a single intra-articular injection.

Mr. Renzi has over 30 years of successful healthcare experience and spent the
majority of this time with Ethicon and Ethicon Endosurgery, divisions of
Johnson & Johnson. There he was given responsibility for numerous business
disciplines including sales, sales management, marketing management and new
procedure development. Most recently, Mr. Renzi was president and chief
executive officer of Neomend, Inc., a company developing and commercializing
hydrogels and surgical sealants for treating lung air leaks after surgical
resection. Neomend was purchased by C.R. Bard in October 2012. Prior to
Neomend, Mr. Renzi was executive vice president and chief commercial officer
of Novacept, Inc. and SurgRx, Inc., both privately held venture-backed
companies with successful exits in 2004 and 2008, respectively.

“I am extremely excited to join the Carbylan team as we continue our
development of a next generation injectable aimed at capturing significant
share in the $2.5 billion viscosupplementation market. This market is growing
by over 11 percent per year and there are nearly 27 million people in the
United States alone who suffer from osteoarthritis. I am confident our
technology will continue to produce meaningful clinical data as we advance our
pivotal trial later this year. This clinically relevant pivotal trial data,
coupled with results from our successful recent phase IIb study, I believe
will allow us to gain regulatory approval and ultimately provide this unique
therapy to the many patients still suffering from the pain of osteoarthritis,”
said Mr. Renzi. “There are many exciting and promising opportunities before
us, and I am very pleased to be involved with Carbylan at this important phase
in the Company’s development cycle.”

“David's significant expertise in growing biotechnology companies into
industry leaders will be critical as we work to move Carbylan’s products
through clinical trials, regulatory approval and ultimately
commercialization," continued Dr. Lynch. "The Company’s platform technology
provides an innovative, proprietary means of addressing a substantial unmet
medical need. David will help us realize our vision for the organization and
future growth plans for our technology."

Dr. Lynch founded BioMimetic Therapeutics, Inc., a biotechnology company
specializing in the development and commercialization of products to promote
the healing of musculoskeletal injuries and diseases in orthopedic and sports
medicine applications, and served as president, chief executive officer and a
director for more than 10 years. He also served as chairman of the board of
directors until the company’s initial public offering (IPO). At BioMimetic,
Dr. Lynch oversaw the company’s financings, including an IPO and follow-on
financings as well as its recent merger with Wright Medical Group, Inc. He
also brings additional expertise in product development and regulatory affairs
to the Carbylan board.

About Carbylan BioSurgery, Inc.

Carbylan (www.carbylan.com) was founded in 2005 to develop and market medical
devices and device/drug combination products based on novel chemically
engineered polymer systems incorporating hyaluronic acid, a well-known
polysaccharide widely present in the human body. Its initial market focus is
therapeutic medical devices and combination products to treat the pain
associated with osteoarthritis. Carbylan biopolymers are novel biomaterials
which when combined with pharmaceutical agents enable the development of
unique medical products.

Contact:

Carbylan BioSurgery
David M. Renzi, 650-855-6770
President & CEO
 
Press spacebar to pause and continue. Press esc to stop.